With the largest diabetic population and a pedigree in metabolic diseases, China is becoming one to watch in diabetes and obesity drug discovery. Diana Turner finds out about an increasingly competitive market. Research by clinical research organisation ICON in late 2025 revealed that China is emerging as a ‘global innovation powerhouse’ in biotech. This has […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!